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566Objectives: This study examined changes in practice and analyzed risk factors for adverse early outcomes after
Fontan surgery through use of a binational, population-based registry.
Methods: Demographic, preoperative, and perioperative data were collected from all participating institutions
of the Australia and New Zealand Fontan Registry. Patient and operative characteristics were analyzed
with multivariable logistic regression for impact on early mortality, early Fontan failure (death, takedown,
or mechanical support), effusions (prolonging hospital stay>30 days or requiring surgical reintervention),
and stay longer than 30 days.
Results: Overall mortality was 3.5% (37/1071) and declined throughout the study period, from 8% (1975-1990) to
4% (1991-2000) and 1% (2001-2010). There were no differences between the extracardiac and lateral tunnel mod-
ifications for anyoutcome.After 2006, the extracardiac conduitwas performedexclusively,with 1.3%mortality. The
proportion of patients with hypoplastic left heart syndrome rose to 17% in the current era, and this group had more
effusions (odds ratio, 3.0; 95% confidence interval, 1.4-6.6) and stayed on average 2 days longer in the hospital. Hy-
poplastic left heart syndromewas also an independent risk factor for composite adverse early outcome (death, failure,
prolonged effusions, or prolonged stay>30 days; odds ratio, 2.6; 95% confidence interval 1.4-4.8 respectively).
Conclusions: The extracardiac conduit is now the exclusive Fontan modification performed in Australia and
New Zealand. Even with a higher proportion of high-risk cases, perioperative outcomes are excellent in the
modern era. Hypoplastic left heart syndrome confers a higher risk of prolonged pleural effusion and early
composite adverse outcome. (J Thorac Cardiovasc Surg 2014;148:566-75)After Fontan and Baudet’s initial description of the atriopul-
monary connection,1 subsequent modifications were
introduced in 1988 by de Leval and colleagues2 and in
1990 by Marcelletti and associates.3 The atriopulmonary
connection has now been abandoned because of the survival
attrition of these patients and the progressive decline in func-
tional capacity.4-6 It has long been assumed that the lateral
tunnel and the extracardiac conduit techniques would yield
equivalent early outcomes, and that differences between
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Congenital Heart Surgery Database, patients undergoing
an extracardiac conduit were found to have a higher risk of
early reintervention and failure and were likely to stay in
the hospital longer than those undergoing the lateral tunnel.7
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Abbreviations and Acronyms
CI ¼ confidence interval
HLHS ¼ hypoplastic left heart syndrome
IQR ¼ interquartile range
OR ¼ odds ratio
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Dproportion of patients with hypoplastic left heart syndrome
(HLHS) reaching Fontan surgery.8
In 2008, the Australia and New Zealand Fontan Registry
was established to clarify long-term expectations of patients
undergoing Fontan procedures and to enable recruitment of
larger numbers of patients into prospective studies. During
the creation and recruitment of patients into this
registry, the preoperative and perioperative data of all
patients undergoing Fontan procedures in Australia and
New Zealand were collected. We thus sought to determine
trends in indications and demographic characteristics of
patients undergoing the Fontan procedure since its
introduction in the region in 1975 and to analyze the impact
of these trends on early outcomes, with a focus on the
surgical techniques used. This analysis represents the entire
experience of Fontan surgery in Australia and New Zealand.
MATERIALS AND METHODS
Institutional approval to collect data at all participating centers was
obtained, and the need for consent was waived because of the retrospective
nature of the study. All Fontan procedures performed in Australia and
New Zealand were identified by consulting the cardiac surgical and
cardiology databases at each institution (Appendix Table 1). Preoperative,
perioperative, and early postoperative data collected are described in
Appendix Table 2. Operative reports, echocardiographic reports, and
discharge summaries were reviewed. Patients for whom insufficient data
existed to satisfy the minimum data set (age at Fontan, Fontan type, and
discharge status) were excluded. Fontan conversions were excluded from
the data set, with the exception of 3 patients who had previously undergone
a Bj€ork procedure and subsequently had a Fontan completion.
Outcomes
The primary outcome was early mortality, defined as death within
the first 30 postoperative days or before hospital discharge if the
stay was longer than 30 days. Secondary outcomes were early failure
(takedown, major reintervention not bleeding related, including Fontan
revision, fenestration creation, enlargement or closure, mechanical
circulatory support, or percutaneous reintervention), prolonged effusions
(lasting>30 days or requiring reoperation for transcatheter intervention,
pleurodesis, or Fontan revision), and a composite adverse early outcome
(death, failure, prolonged effusions, or prolonged stay>30 days).
Statistical Analysis
Patient, operative and outcome data were described according to era and
Fontan type (Tables 1 and 2), with normally distributed, nonnormally
distributed, and proportional data described as mean  SD, median with
interquartile range (IQR), and number and percentage, respectively.
Logistic regression analysis models were constructed for each outcome,
and multivariable models were designed a priori to compare lateral
tunnel versus extracardiac Fontan types and morphologically left versus
right ventricles while adjusting for sex, age, and morphology asThe Journal of Thoracic and Cacategoric variables. Remaining covariates were analyzed in univariable
models to identify potential confounders and entered into the
multivariable models if they were associated with a large effect size
(odds ratio (OR) 2.5 or 0.4) or there was evidence against the null
hypothesis of no association (2-tailed P  .05). Because of collinearity
between Fontan type, era, staging with bidirectional cavopulmonary
shunt, and fenestration, we included only Fontan type in multivariable
models. Additionally, southern hemisphere respiratory syncytial virus
season (the months of May to September) was analyzed for its effect on
pleural effusions. The variables selected for multivariable models and
their regression parameters are reported in Table 3.
Exposure groups in which no failures or deaths occurred could not be
entered into logistic regression models. Numeric covariates were
analyzed as continuous variables unless a nonlinear relationship could be
demonstrated between covariate and outcome. Linearity was examined
by performing a likelihood ratio test comparing regression models with
continuous covariates against models in which the numeric variable had
been categorically transformed. Age at Fontan operation had nonlinear
associations with mortality (Figure 1) and the other end points and was
analyzed as a categoric variable.
All analyses were performed with the Stata 11.2 statistical software
package (StataCorp, College Station, Tex).RESULTS
Description of Cohort
In all, 1095 Fontan procedures were identified, of
which 1071 had sufficient data to be included for analysis.
A total of 1989 previous surgical palliations were per-
formed in 990 patients. Previous staging with bidirectional
cavopulmonary shunt occurred in 636 patients (59%): 4%
who underwent the atriopulmonary technique, 16% who un-
derwent lateral tunnel, and 96%who underwent extracardiac
conduit. Mean pre-Fontan pulmonary arterial pressure was
lowest among patients with extracardiac conduits (11.1 
2.7mmHg for extracardiac, 12.5 4.5mmHg for lateral tun-
nel, and 13.1  4.3 mm Hg for atriopulmonary; P< .001;
R2 ¼ 0.05). The proportion with detected aortopulmonary
collaterals increased with each era (3 patients [3%] before
1991, 47 patients [16%] from 1991 to 2000, and 115
patients [30%] after 2000), and 46 of 165 patients (28%)
had these embolized before the Fontan procedure by
transcatheter coiling. At 1 center, internal thoracic to pulmo-
nary artery collaterals were routinely divided at operation if
visualized.
Moderate or severe atrioventricular valve regurgitation
was present before the Fontan procedure in a total of
65 patients (7.5%). Of the whole cohort, 40 patients
(4.6%) had previously undergone atrioventricular valve
repair or replacement; 18 (45%) were left with recurrent
regurgitation by the time of the Fontan procedure, but re-
repair was only attempted in 9 patients. Atrioventricular
valve repair was undertaken concomitantly with the Fontan
procedure in 28 patients (3%, 9 re-repairs and 19 de novo
repairs).
Extracardiac conduit was the only modification
performed after July 2006. Fenestration was performed in
50% of lateral tunnel and 44% of extracardiac connections.rdiovascular Surgery c Volume 148, Number 2 567
TABLE 1. Description of baseline data by Fontan type
Variable AP (1975-1995) LT (1988-2006) ECC (1997-2010) Total
No. of patients 239 (22%) 296 (28%) 536 (50%) 1071
Age (y, median and IQR) 5.6 (3.2-9.3) 3.8 (2.8-5.8) 4.8 (3.9-6.0) 4.7 (3.4-6.5)
Male (No.) 132 (55%) 166 (56%) 320 (60%) 618 (58%)
Ventricular morphology
Left 185 (77%) 183 (62%) 289 (54%) 657 (61%)
Right 44 (18%) 93 (32%) 190 (36%) 327 (31%)
Biventricular/indeterminate 10 (4%) 19 (6%) 57 (11%) 86 (8%)
Morphologic group
TA 79 (33%) 73 (25%) 101 (19%) 253 (24%)
HLHS 2 (1%) 9 (3%) 78 (15%) 89 (8%)
DORV 34 (14%) 45 (15%) 71 (13%) 150 (14%)
CAVC 13 (5%) 17 (6%) 34 (6%) 64 (6%)
TGA 6 (3%) 18 (6%) 27 (5%) 51 (5%)
ccTGA 10 (4%) 13 (4%) 28 (5%) 51 (5%)
DILV 52 (22%) 65 (22%) 78 (15%) 195 (18%)
PA-IVS 17 (7%) 20 (7%) 47 (9%) 84 (8%)
CAVC-DORV 6 (3%) 16 (5%) 26 (5%) 48 (4%)
Other 20 (8%) 20 (7%) 46 (9%) 86 (8%)
Anatomic comorbidities
Isomerism or heterotaxy 11 (5%) 22 (7%) 39 (7%) 72 (7%)
Dextrocardia or mesocardia 22 (9%) 18 (6%) 39 (7%) 79 (7%)
Previous operations
No. (mean  SD) 1.2  0.8 1.6  0.9 2.3  1.0 1.9  1.0
PA banding (No. and%) 55 (23%) 86 (29%) 141 (26%) 282 (26%)
Norwood procedure (No. and%) 2 (1%) 10 (3%) 81 (15%) 93 (9%)
Aortic arch intervention (No. and%) 17 (7%) 48 (16%) 185 (35%) 250 (23%)
BCPS (No. and%) 9 (4%) 111 (38%) 516 (96%) 636 (59%)
PA reconstruction (No. and%) 5 (2%) 18 (6%) 113 (21%) 136 (13%)
Pre-Fontan hemodynamics
Arterial oxygen saturation (per%, median and IQR; n ¼ 839) 81 (77-85) 82 (78-85) 82 (78-86) 82 (78-86)
PA pressure (mm Hg, mean  SD; n ¼ 869) 13.1  4.3 12.5  4.5 11.1  2.7 11.9  3.7
 Moderate AV valve regurgitation (No.; n ¼ 871) 9 (8%) 12 (5%) 44 (9%) 65 (7%)
Arteriovenous malformations (No.; n ¼ 809) 2 (2%) 6 (3%) 32 (7%) 40 (5%)
Collaterals (No.; n ¼ 799) 2 (2%) 21 (10%) 142 (29%) 165 (21%)
Operative variables (No.)
Concomitant procedure 31 (13%) 52 (18%) 73 (14%) 156 (15%)
Fenestration 0 (0%) 149 (50%) 236 (44%) 385 (36%)
RSV seasonality (May to September) 108 (45%) 130 (44%) 183 (34%) 421 (39%)
When data were not available for all patients, values are given for study set and study set size is specified. AP, Atriopulmonary; LT, lateral tunnel; ECC, extracardiac conduit;
IQR, interquartile range; TA, tricuspid atresia; HLHS, hypoplastic left heart syndrome; DORV, double-outlet right ventricle; CAVC, complete atrioventricular canal;
TGA, transposition of the great arteries; ccTGA, congenitally corrected transposition of the great arteries; DILV, double-inlet left ventricle; PA-IVS, pulmonary atresia with intact
ventricular septum; PA, pulmonary artery; BCPS, bidirectional cavopulmonary shunt; AV, atrioventricular; RSV, respiratory syncytial virus.
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DPulmonary artery rehabilitation (percutaneous or surgical)
was undertaken in a total of 191 patients (18%) at some
stage during life: 55 patients underwent pulmonary artery
patch reconstruction at the time of the Fontan procedure,
126 had surgical reconstruction or stenting before Fontan
completion, and an additional 10 had both previous and
concomitant intervention to the pulmonary arteries.
Age at Fontan completion varied according to Fontan
type. The extracardiac conduit was performed 1 year
later than the lateral tunnel (median, 4.8 years; IQR,
3.9-6.0 years; vs median, 3.8 years; IQR, 2.8-5.8 years;
P<.001).568 The Journal of Thoracic and Cardiovascular SurgThe proportion of patients with HLHS rose during the
regional experience, from 1% in the era to 1990, to 3%
between 1991 and 2000 and 17% after 2000. The peak
proportion of patients undergoing Fontan surgery with
HLHS was 28% in 2007. HLHS was present in 15% of
patients undergoing extracardiac Fontan procedures.
Early Mortality
The early outcomes of patients are represented
graphically in Figure 2 and in tabular form in Tables 2
and 4. Results of logistic regression analysis for each
outcome are presented in Table 3.ery c August 2014
TABLE 3. Univariate and multivariate logistic regression results for each end point
Variable
Early mortality (n ¼ 37) Early failure (n ¼ 65) Prolonged effusions (n ¼ 75)
Composite adverse early
outcome (n ¼ 165)
Univariate Multivariate Univariate Multivariate Univariate Multivariate Univariate Multivariate
P
value OR
95%
CI
P
value
P
value OR
95%
CI
P
value
P
value OR
95%
CI
P
value
P
value OR
95%
CI
P
value
Fontan type
Lateral tunnel Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref
Atriopulmonary <.001 3.9 1.1-13.2 .03 .05 1.7 0.6-4.9 .4 .5 0.9 0.4-1.9 .7 .006 1.6 0.7-3.6 .3
Extracardiac
conduit
.4 1.2 0.3-4.6 .8 .2 0.6 0.2-1.3 .2 .2 1.1 0.6-2.0 .7 .2 0.9 0.5-1.6 .7
Age (y)
4-5 Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref
<4 .05 4.5 0.6-37 .2 .3 1.2 0.5-3.2 .9 .04 0.6 0.3-1.1 .08 .3 0.7 0.4-1.3 .2
5-8 .09 3.6 0.4-32 .2 .6 0.9 0.3-2.8 .9 .04 0.5 0.3-1.0 .05 .3 0.5 0.3-1.1 .07
>8 .01 6.5 0.8-55 .09 .2 1.5 0.5-4.7 .5 .05 0.5 0.2-1.2 .1 .6 0.7 0.3-1.5 .4
Male sex .6 1.2 0.7-4.5 .2 .2 1.8 0.9-3.9 .1 .9 0.8 0.5-1.3 .4 .5 0.8 0.5-1.3 .3
Ventricular morphology
Left Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref
Right .8 .9 0.8 0.3-1.7 .5 .01 1.2 0.7-2.2 .5 .4
BiVor
indeterminate
.3 .09 2.2 0.8-6.5 .1 .6 1.3 0.5-3.2 .6 .5
Morphologic group
TA Ref Ref Ref * Ref Ref Ref Ref
HLHS .4 .6 <.001 3.1 1.4-6.6 .005 .02 2.7 1.2-6.0 .01
DORV .9 .9 >.99 .4 1.0 0.4-2.3 >.99
CAVC .9 .4 .6 .06 2.1 0.8-5.3 .1
TGA —y .2 .7 .8 1.2 0.3-4.6 .8
ccTGA .4 .4 .4 .2 1.5 0.5-4.3 .4
DILV .3 .3 .4 .4 1.1 0.5-2.3 .9
PA-IVS .8 .9 .7 >.99 1.0 0.4-2.8 >.99
CAVC-DORV .3 .3 .3 .3 2.0 0.6-6.6 .2
Other .4 .2 .2 .7 0.9 0.3-2.4 .8
Anatomic comorbidities
Isomerism or
heterotaxy
.3 .07 .3 .07
Dextrocardia
or mesocardia
.2 .04 2.3 0.8-6.4 .1 .5 .04 1.4 0.6-3.3 .4
Previous operations
No. .003 1.0 0.6-1.6 .9 .06 .1 .01 0.9 0.7-1.2 .7
PA banding .2 .8 .9 .7
Aortic arch
intervention
.2 .8 .001 —z .3
(Continued)
TABLE 2. Description of early outcomes according to era
Outcome 1975-1990 1991-2000 2001-2010 Total
No. 246 (23%) 371 (35%) 454 (42%) 1071
Early mortality 19 (8%) 13 (4%) 5 (1%) 37 (3.5%)
Early failure* 21 (9%) 27 (7%) 17 (4%) 65 (6%)
Prolonged effusionsy 11 (4%) 28 (8%) 35 (8%) 74 (7%)
Composite adverse early outcomez 48 (26%) 61 (20%) 56 (12%) 165 (17%)
Prolonged stay (>30 d) 29 (16%) 37 (12%) 44 (10%) 110 (12%)
Stay among survivors (d, median and IQR; n ¼ 913) 15.5 (12-27) 12 (9-20) 13 (9-20) 13 (10-21)
Data are expressed as No. and% except as specified. IQR, Interquartile range. *Death, mechanical support, takedown, or major reoperation. yPleural effusions persisting>30
days or requiring surgical intervention. zProlonged effusions, failure, or prolonged stay (>30 days).
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TABLE 3. Continued
Variable
Early mortality (n ¼ 37) Early failure (n ¼ 65) Prolonged effusions (n ¼ 75)
Composite adverse early
outcome (n ¼ 165)
Univariate Multivariate Univariate Multivariate Univariate Multivariate Univariate Multivariate
P
value OR
95%
CI
P
value
P
value OR
95%
CI
P
value
P
value OR
95%
CI
P
value
P
value OR
95%
CI
P
value
BCPS <.001 —x .003 —x .09 <.001 —x
Previous or
concomitant PA
reconstruction
.8 .6 .2 .9
Pre-Fontan hemodynamicsk
Arterial oxygen
saturation, (per%;
n ¼ 839)
.2 .1 .3 .1
PA pressure
(per 5 mm Hg;
n ¼ 869)
.01 1.5 1.0-2.4 .06 .003 1.4 1.0-2.1 .08 .4 .03 1.3 0.9-1.8 .1
AV valve
regurgitation
(n ¼ 871)
—y .08 0.4 0.04-3.0 .3 .5 .6
Arteriovenous
malformations
(n ¼ 809)
.1 .08 2.1 0.6-7.2 .3 .2 .03 2.6 1.2-5.8 .02
Collaterals
(n ¼ 799)
.6 .08 .09 .5
Operative variables
Concomitant
procedure
.1 2.2 0.8-6.0 0.1 .2 .007 2.2 1.2-3.8 .008 .01 1.9 1.1-3.3 .02
Fenestration .007 —x .2 .1 .04 —x
Postoperative
effusions
(mortality and
failure end
points only)
.3 <.001 14.5 6.5-32.5<.001 — —
RSV seasonality
(May-Sept
prolonged effusions
end point only)
— — .8 —
Regression parameters are presented for covariates entered into multivariate models. OR, Odds ratio; CI, confidence interval; Ref, reference; BiV, biventricular; TA, tricuspid
atresia; HLHS, hypoplastic left heart syndrome; DORV, double-outlet right ventricle; CAVC, complete atrioventricular canal; TGA, transposition of the great arteries;
ccTGA, congenitally corrected transposition of the great arteries; DILV, double-inlet left ventricle; PA-IVS, pulmonary atresia with intact ventricular septum; PA, pulmonary
artery; BCPS, bidirectional cavopulmonary shunt; AV, atrioventricular; RSV, respiratory syncytial virus. *Odds ratio for HLHS versus all other morphologies as reference group.
yExcluded from analysis because of no failures in exposed group. zExcluded from analysis because of collinearity with HLHS morphology (multivariate). xExcluded from
analysis because of collinearity with Fontan type (multivariate). kData available for n patients.
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DThere were a total of 37 early deaths: 2 intraoperative, 3
after reintervention, 5 after takedown, and 26 not associated
with any major reintervention. Early mortalities after
extracardiac conduit and lateral tunnel modifications were
low (7/536 [1.3%] and 6/296 [2.0%], respectively;
P ¼ .4), with higher early mortality after atriopulmonary
connection (24/239 [10%]). A 1% mortality was achieved
in the current era (Table 2). Risk factors associated with
early mortality after adjustment for age and sex were atrio-
pulmonary connection technique (OR, 3.9; 95% CI, 1.1-
13.2) and preoperative elevation of pulmonary arterial570 The Journal of Thoracic and Cardiovascular Surgpressure (OR, 1.5 per 5–mm Hg increase; 95% CI, 1.0-
2.4). Mortalities after lateral tunnel and extracardiac
conduit did not differ (OR, 1.2; 95% CI, 0.3-4.6) indepen-
dent of era. Fontan completion at 4 to 5 years of age was
weakly associated with markedly lower univariate odds of
mortality when compared with those younger than 4 years
(OR, 4.5; 95% CI, 0.6-37), 5 to 8 years old (OR, 3.6;
95% CI, 0.4-32), and older than 8 years (OR, 6.5; 95%
CI, 0.8-55). Despite large effect sizes in univariate models,
however, the age of completion no longer reached statistical
significance in the multivariate model.ery c August 2014
FIGURE 1. Probability of early mortality against age at Fontan, obtained
by means of fractional polynomial regression. Dashed lines indicate upper
and lower 95% confidence limits.
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DEarly Failure (Death, Takedown, Major
Reintervention, or Mechanical Circulatory Support)
Early failure occurred in 6% of patients (65/1071).
Among the 20 patients undergoing early Fontan takedown,
15 (75%) survived to hospital discharge with an
intermediate palliation (10 bidirectional cavopulmonary
shunts, 2 central shunts, 2 hemi-Fontan procedures, and
1 Kawashima procedure; Figure 2). In total, 5 patients
required mechanical circulatory support (extracorporealFIGURE 2. Surgical progression and early outcomes. AP, Atriopulmonary; L
membrane oxygenation; VAD, ventricular assist device; BCPS, bidirectional ca
The Journal of Thoracic and Camembrane oxygenation, n ¼ 4; ventricular assist device,
n ¼ 1), 3 of whom survived to hospital discharge. Two of
these patients were put on extracorporeal membrane
oxygenation after early reintervention (1 each revision
and takedown). Prolonged pleural effusion was the only
independent predictor of increased risk of early failure
(OR, 14.5; 95% CI, 6.5-32.5). There were no deaths or
failures among the 40 patients who had undergone
concomitant or previous atrioventricular valve repair or
replacement.
Pleural Effusions, Prolonged Stay, and Composite
Adverse Early Outcome
Prolonged effusions occurred in 74 patients (7%), and the
mortality among these patients was 5% (4/74, univariate
P¼ .8). In 37 of these patients, 61 reoperations were under-
taken; these included 7 takedowns, 9 revisions, 1 conversion,
9 embolizations or division of collaterals, 20 pleurodeses, 3
percutaneous fenestration dilatations, and 1 thoracic duct
ligation. In multivariable models, HLHS and concomitant
procedure at the time of the Fontan operation were strongly
associated with prolonged effusions (OR, 3.1; 95% CI, 1.4-
6.6; and OR, 2.2; 95% CI, 1.2-3.8, respectively). There was
no association between prolonged effusions and Fontan
completion during the southern hemisphere respiratory syn-
cytial virus season (May to September).T, lateral tunnel; ECC, extracardiac; pts, patients; ECMO, extracorporeal
vopulmonary shunt.
rdiovascular Surgery c Volume 148, Number 2 571
TABLE 4. Description of early outcomes according to Fontan type
Outcome AP LT ECC Total
No. 239 (22%) 296 (28%) 536 (50%) 1071
Early mortality 24 (10%) 6 (2.0%) 7 (1.3%) 37 (3.5%)
Early failure* 26 (11%) 18 (6%) 21 (4%) 65 (6%)
Prolonged effusionsy 11 (5%) 18 (6%) 45 (8%) 74 (7%)
Composite adverse early
outcomez
55 (29%) 39 (17%) 71 (13%) 165 (17%)
Prolonged stay (>30 d) 31 (16%) 26 (12%) 53 (10%) 110 (12%)
Stay among survivors (d,
median and IQR; n ¼ 913)
16 (12-27) 12 (10-20) 13 (9-20) 13 (10-21)
Data are expressed as No. and% except as specified. AP, Atriopulmonary; LT, lateral tunnel; ECC, extracardiac conduit; IQR, interquartile range. *Death, mechanical support,
takedown, or major reoperation. yPleural effusions persisting>30 days or requiring surgical intervention. zProlonged effusions, failure, or prolonged stay (>30 days).
Congenital Heart Disease Iyengar et al
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patients with HLHS and atrioventricular septal defects,
respectively, stayed 2 and 5 days longer than other groups
(P ¼ .04 and P ¼ .008), and this was the principal driver
for the identification of HLHS as the strongest independent
predictor (OR, 2.7; 95% CI, 1.2-6.0) of the composite
adverse early outcome end point (death, failure, prolonged
effusions, or stay>30 days). The remaining independent
risk factors are presented in Table 4.
Permanent pacemaker was required by discharge in
23 patients (2%; atriopulmonary, n ¼ 8; lateral tunnel,
n ¼ 4; extracardiac conduit, n ¼ 11).
DISCUSSION
Our study is based on a unique, binational population-
based registry that captures all available patients
undergoing a Fontan procedure. We believe this design
provides the most accurate data by eliminating potential
referral and selection bias, as well as exploring outcomes
for patients undergoing similar procedures in different
institutions.
Trends in Fontan Surgery
It is likely that our experience in Australia and
New Zealand reflects changes in Fontan surgery evident
elsewhere. The preoperative condition of patients has
improved, as reflected by the decrease in the proportion of
patients with elevated preoperative pulmonary arterial
pressures. It is remarkable that today the Fontan procedure
has become an operation with 1% to 2% early mortality
and a rate of early failure of 4%. We have replaced
the atriopulmonary technique, which was associated
with worse outcomes,5 with the lateral tunnel and now
extracardiac modifications.
The most striking change seen in our practice in the last
decade has been the increasing proportion of patients
with HLHS who are offered Fontan surgery, which is
the direct result of the improved survival of these patients
after their initial surgeries. This subset of patients
represents the worst end of the spectrum of patients572 The Journal of Thoracic and Cardiovascular Surgoffered Fontan surgery,9,10 and it is therefore remarkable
that the mortality associated with Fontan surgery has
decreased during the same period, remaining around 1%
in Australia and New Zealand. It is likely that a better
understanding of the Fontan physiology, and resultant
better patient selection, has improved the preoperative
and postoperative management of patients. In
particular, the improved care of atrioventricular valve
regurgitation,11,12 collaterals,13 and pulmonary arteriove-
nous malformations have probably contributed to these
improved outcomes. This increasing population with
HLHS have low mortality similar to that of the other
patients but create increased demands on the health
system. Disproportionate use of inpatient cardiac critical
care services by single-ventricle patients, in particular
those with HLHS, has already been observed.14,15 Our
study highlights that they have more early adverse
outcomes and stay longer in the hospital because of
their tendency to have prolonged effusions. This
association had already been demonstrated by Gaynor
and colleagues16 and Rogers and associates17 and cannot
be clearly linked only to adverse morphology. Patients
with HLHS have undergone more extensive surgery during
earlier operations. It is possible that previous damage to
the network of chylous channels around the aorta during
the initial surgery and repetitive extensive dissections
predispose these patients toward chyle leaks. The recent
report of Stewart and coworkers7 demonstrated that
patients undergoing an extracardiac conduit were at risk
for prolonged hospital stay, and we have hypothesized
that this may be related to more extensive dissection
with this technique.18 The prolonged effusions observed
in patients with HLHS could also be related to adverse
physiologic characteristics not apparent in Stewart and
coworkers’ earlier study,7 such as a trend toward more
atrioventricular valve regurgitation, more aortopulmonary
collaterals, or higher end-diastolic ventricular pressure.
One wonders whether patients like these who have a
higher rate of early complications will perhaps be prone
to earlier failure of the Fontan circulation.ery c August 2014
Iyengar et al Congenital Heart Disease
C
H
DFontan Type and Age at Fontan Completion
There has been little clinical evidence that either of
the prevailing techniques, the lateral tunnel and the
extracardiac cardiac conduit, is superior to the other.
Nevertheless, theoretic advantages have led all teams in
Australia and New Zealand independently to adopt the
extracardiac conduit technique.
Importantly, in our experience, there were no differences
in the odds of development of any adverse early outcome be-
tween the lateral tunnel and extracardiac conduit
modifications. This is in contrast to the recently published
findings of Stewart and coworkers,7 who demonstrated
increased odds of Fontan takedown, revision, Fontan
failure, and longer postoperative stay after the extracardiac
modification than after the lateral tunnel. The key difference
between our series is the age at elective Fontan completion.
Stewart and coworkers7 explicitly excluded patients older
than 6 years from the analysis; however, these patients
represent 30% of our cohort (318/1071). The reportedNorth
American experience reflects a willingness to proceed with
Fontan completion at a very early age, with half of the pa-
tients operated on younger than 3 years. In Australia and
New Zealand, by contrast, Fontan completion is undertaken
at a later age, at a median of 4.7 years in the current era, and
fewer than 7% of contemporary patients in this series had
their Fontan procedure completed before the age of 3 years.
The use of the lateral tunnel may be advantageous at such an
early age, because the use of the extracardiac conduit will
result in a size discrepancy between the adult-sized conduit
and small vascular structures. Conduit size and the ratio of
inferior vena cava to conduit diameter may be an important
determinant of early outcomes, as the use of a conduit that is
too large in a small patient promotes stagnation of caval flow
andmay contribute to loss of the respiratory pump, essential
for inspiratory augmentation of pulmonary blood flow, and
promote thrombosis formation in the early post-
operative period.19,20 We have previously suggested that
construction of the extracardiac conduit may be more
prone to subtle technical deficiencies, such as distortion of
the pulmonary arteries and a suboptimal fenestration,
which are difficult to analyze without imaging data.18 These
factors may also play a role in early hemodynamics and thus
in outcomes.
We were interested to find that in our practice the age of
4 to 5 years was associated with better outcome according to
univariate analysis but not in the multivariate model. It can
be easily understood that within a policy of completing the
Fontan around 4 years, patients younger than 4 years would
be a select group with worse symptoms, such as those
with pulmonary arteriovenous malformations and severe
cyanosis. It is notable that later age at surgery seems to be
associated with worse late functional outcomes but also
worse early outcomes.21The Journal of Thoracic and CaAtrioventricular Valve Regurgitation
Atrioventricular valve regurgitation in patients with a
single ventricle is likely to become an increasing issue in
our patient population, and it appears to evolve to signifi-
cantly adversely affect the course of patients during staged
palliation despite an absence of truly discouraging long-
term survival data.5,22,23 One in 10 patients in this series
either displayed moderate to severe regurgitation
immediately preoperatively, had previously undergone
valve repair or replacement, or underwent repair or
replacement at the time of the Fontan procedure. This
series validates that excellent outcomes for these patients
can be expected in the short term,24 despite a trend toward
more effusions in those who undergo concomitant surgery.Limitations
This study is limited by its retrospective nature. Direct
comparisons between different surgical modifications are
clearly confounded by the fact that these were under-
taken during different eras during the binational experi-
ence. Because of the very close correlation between
era and atriopulmonary Fontan type, correction for era
was not possible. It is thus not possible to conclude
whether the poorer outcomes after the atriopulmonary
Fontan procedure were driven primarily by the early
era during which these procedures were undertaken or
by the procedure itself. In reality, we suspect a combina-
tion of these factors.
Similarly, staging could not be analyzed in multivariable
models because it was so strongly associated with the
development of the later Fontan modifications. We have
previously demonstrated that the introduction of staging
before Fontan completion entailed a selection process.25
Finally, this registry does not encompass all patients with
single-ventricle physiology. This means that the true
selection bias is not quantifiable, and the size of the era
effect on patient selection is not known.CONCLUSIONS
In conclusion, in Australia and New Zealand, all centers
have progressively adopted the extracardiac conduit tech-
nique and offer Fontan surgery to patients around 4 to
5 years old. In this setting, the extracardiac conduit can
be performed with a mortality of 1% and achieve similar
early outcomes to the lateral tunnel. Patients with HLHS
have more early complications, in particular pleural effu-
sions, and this makes them a greater burden on delivery
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APPENDIX TABLE 2. Variables collected
Patient characteristics
Demographic characteristics
Sex
Age (grouped<4, 4 to 5, 5 to 8, 8)
Year of Fontan (grouped: 1975-1990, 1991-2000, 2001-2010 )
Diagnosis
Tricuspid atresia
Hypoplastic left heart syndrome
Double outlet right ventricle
Complete atrioventricular canal
Transposition of the great arteries
Congenitally corrected transposition
Double inlet left ventricle
Pulmonary atresia with intact ventricular septum
Complete atrioventricular canal with double outlet right ventricle
Other
Morphology
Dextrocardia or mesocardia
Presence of common atrioventricular valve
Ventricular morphology (grouped: left, right, indeterminate,
biventricular)
Previous surgery
Pulmonary artery band
Aortic arch procedure (including Damus, Norwood, or arch
reconstruction)
Pulmonary artery reconstruction before or at time of Fontan
Atrioventricular valve repair before or at time of Fontan
Bidirectional cavopulmonary shunt (grouped: unilateral, bilateral,
Kawashima, hemi-Fontan)
Preoperative hemodynamics
Mean pulmonary arterial pressure
Arterial oxygen saturation
Atrioventricular valve regurgitation (graded moderate or greater)
Operative characteristics
Type of Fontan
Atriopulmonary
Lateral tunnel
Extracardiac conduit
Procedure related
Presence of fenestration
Concomitant procedures
Postoperative course
Mortality during initial hospital stay or within 30 d
Length of stay (prolonged if>30 d)
Mechanical circulatory support (ECMO or VAD)
Major reoperation (including takedown, revision, or permanent
pacemaker)
Effusions requiring reoperation or prolonging hospital stay>30 d
ECMO, Extracorporeal membrane oxygenation; VAD, ventricular assist device.
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